Staff & Wire Reports-UnitedHealth Group's Chair and CEO William W. McGuire, MD, has stepped down as chairman of the board and will resign as CEO on Dec. 1, following the release of a report that found that Dr. McGuire likely received backdated stock options.
STAFF & WIRE REPORTS-UnitedHealth Group's Chair and CEO William W. McGuire, MD, has stepped down as chairman of the board and will resign as CEO on Dec. 1, following the release of a report that found that Dr. McGuire likely received backdated stock options.
According to an Oct. 15 UnitedHealth Group company statement outlining a series of actions, the UnitedHealth Group Board elected Stephen J. Hemsley to succeed Dr. McGuire as CEO upon his departure from the company. Hemsley joined the company in 1997 and has been president and COO since 1999.
According to Clive Riddle, president and founder of MCOL, a provider of business-to-business health management and managed care resources, during Dr. McGuire's time at UnitedHealth, the company's stock increased a multiple of 56 times.
In February, a United press release announced Dr. McGuire's exercise of 2.3 million shares of stock to support philanthropic commitments and for financial diversification purposes, according to Riddle. "Never in a million years do I think Dr. McGuire or United imagined at that time, that they did anything wrong or that the transaction would help trigger the firestorm that it did," he says.
BIG FISH
"United got caught in the backdating scandal because they are a big and very visible fish," Riddle continues. "But there will be other large healthcare companies ultimately caught in this net as well. More importantly, most of the companies caught in this scandal have nothing to do with healthcare. You just have to be a public company, be fairly visible, have stock options and participated in a practice that has indeed been widespread to now operate under a cloud."
UnitedHealth Group could not be reached for comment.
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Roflumilast Foam Showed Strong Results for Scalp and Body Psoriasis in Teens and Adults
May 7th 2025A new JAMA Dermatology study found that once-daily Zoryve (roflumilast) foam, 0.3%, safely and effectively reduced scalp and body plaque psoriasis symptoms in patients 12 and older, offering a convenient, and more tolerated treatment option that may boost adherence and quality of life.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Time Well Spent: Lung Cancer Trials Offer Improved Survival Without Added Burden
May 7th 2025Researchers are exploring the topic of "time toxicity" — how much time patients spend receiving care. This study is the first to directly compare time spent in care between clinical trial participants and routine care patients receiving the same treatments.
Read More
Depend on Biomakers, Not Symptoms, for Diagnosis, Early Treatment of GVHD, Experts Argue
May 7th 2025John Levine, M.D., a graft-versus-host-disease expert at the Icahn School of Medicine at Mount Sinai in New York, makes a case for biomarkers in a review article published in the American Journal of Hematology.
Read More